Dr. McKay Discusses the CheckMate-214 Trial in RCC

Rana R. McKay, MD
Published: Monday, Sep 25, 2017



Rana R. McKay, MD, medical oncologist, assistant professor, Moores Cancer Center at the University of California, San Diego, discusses the CheckMate-214 study in renal cell carcinoma (RCC).

The phase III CheckMate-214 study evaluated the combination of nivolumab (Opdivo) plus ipilimumab (Yervoy) for patients with metastatic clear cell RCC.

This was the first time that an agent had beat sunitinib (Sutent) in the first-line space, says McKay, but there is still a lot to be learned with this combination regarding patient selection.
 


Rana R. McKay, MD, medical oncologist, assistant professor, Moores Cancer Center at the University of California, San Diego, discusses the CheckMate-214 study in renal cell carcinoma (RCC).

The phase III CheckMate-214 study evaluated the combination of nivolumab (Opdivo) plus ipilimumab (Yervoy) for patients with metastatic clear cell RCC.

This was the first time that an agent had beat sunitinib (Sutent) in the first-line space, says McKay, but there is still a lot to be learned with this combination regarding patient selection.
 

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Community Practice Connections™: Personalized Sequencing in Castration-Resistant Prostate Cancer: Bridging the Latest Evidence to the Bedside in Clinical ManagementAug 25, 20181.5
Community Practice Connections™: Medical Crossfire®: Translating Lessons Learned with PARP Inhibition to the Treatment of Breast Cancer—Expert Exchanges on Novel Strategies to Personalize CareAug 29, 20181.5
Publication Bottom Border
Border Publication
x